Boehringer Must Show How IP 'Thicket' Blocked Humira Rival

By Tiffany Hu (February 25, 2019, 5:39 PM EST) -- Boehringer Ingelheim must hand over its launch plans for a biosimilar version of AbbVie Inc.'s hugely popular immunosuppressant Humira, a Delaware magistrate judge has ruled in a patent infringement case, finding the information is relevant to Boehringer's defense that AbbVie created an illegitimate, anti-competitive "thicket" of duplicative and unoriginal patents....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!